Lantern Pharma's AI-Driven Cancer Drug Shows Promise in Phase 1 Trial
December 3, 2025 — Lantern Pharma reports positive Phase 1 results for AI-developed cancer drug LP-184, showing safety and efficacy in advanced solid tumors with $10B+ market potential.